EU ATMP Developers Missing Out By Failing To Use Advice On Offer
Executive SummaryRegulators and health technology assessment officials in the EU are disappointed that sponsors of advanced therapy medicinal products are not making good use of the joint scientific advice service, which can help converge regulatory and HTA requirements for these products.
You may also be interested in...
The EU research-based pharmaceutical industry has welcomed the launch of a new single gateway for companies to seek parallel scientific advice from the European Medicines Agency and health technology assessment bodies on initial evidence generation and post-authorization data collection. The industry hopes the initiative will help deliver one single evidence package for regulatory and HTA purposes.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.